Clinical Trial Disappointment for This Pharmaceutical Giant

Before you go, we thought you'd like these...
Before you go close icon

More than 10 million people around the world suffer from Parkinson's disease, according to the Parkinson's Disease Foundation. Unfortunately, pharmaceutical company Merck announced last week that it will halt the development of an experimental drug for this indication because of disappointing clinical data. Does Merck have other drugs in development for this disease? Are smaller biotechs making progress in this space? Health-care analyst Max Macaluso discusses these questions in the following video.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.

The article Clinical Trial Disappointment for This Pharmaceutical Giant originally appeared on

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading